GSK to license Hutchmed’s KRAS-EGFR cancer drug for $110M upfront
GSK will spend $110 million upfront for a license to a KRAS-EGFR antibody conjugate developed by Hutchmed, with up to $1.185 billion in biobucks on the line. The Chinese biopharma said ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.